Evidence map›Paper›PMID 34910103›Full record

ArticleTranslational vision science & technology2021

Visual Field Progression in Glaucoma: Comparison Between PoPLR and ANSWERS.

Iván Marín-Franch, Paul H Artes, Andrew Turpin, Lyne Racette

Abstract read
In one paragraph

Article in Translational vision science & technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Iván Marín-FranchComputational Optometry, Atarfe, Granada, Spain.
Paul H ArtesSouthwest Eye Institute, Tavistock, UK.
Andrew TurpinSchool of Computing and Information Systems, University of Melbourne, Australia.
Lyne RacetteDepartment of Ophthalmology and Visual Sciences, University of Alabama, Alabama, USA.

Funding

African Descent And Glaucoma Evaluation Study (ADAGES)U10EY014267 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2002 to 2010
$13.2M
Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma:Structural AssessmentR01EY011008 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 1995 to 2015
$8.7M
Diagnostic Innovations in Glaucoma Study (DIGS): Functional ImpairmentR01EY021818 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MEDEIROS, FELIPE · 2011 to 2015
$3.4M
Functional Testing for GlaucomaR01EY020922 · NEI · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI GARDINER, STUART · 2011 to 2021
$3.2M
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma ProgressionR01EY019869 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2010 to 2014
$2.8M
Early detection of glaucoma progression using a novel individualized approachR01EY025756 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RACETTE, LYNE · 2016 to 2021
$1.9M
Predicting the rate of progression in glaucomaR01EY019674 · NEI · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI DEMIREL, SHABAN · 2009 to 2013
$1.8M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY011008NEI NIH HHS R01 EY019674NEI NIH HHS R01 EY019869NEI NIH HHS R01 EY020922NEI NIH HHS R01 EY021818NEI NIH HHS R01 EY025756NEI NIH HHS U10 EY014267
6 · The paper itself

Abstract

Purpose: It has been suggested that the detection of visual field progression can be improved by modeling statistical properties of the data such as the increasing retest variability and the spatial correlation among visual field locations. We compared a method that models those properties, Analysis with Non-Stationary Weibull Error Regression and Spatial Enhancement (ANSWERS), against a simpler one that does not, Permutation of Pointwise Linear Regression (PoPLR). Methods: Visual field series from three independent longitudinal studies in patients with glaucoma were used to compare the positive rate of PoPLR and ANSWERS. To estimate the false-positive rate, the same visual field series were randomly re-ordered in time. The first dataset consisted of series of 7 visual fields from 101 eyes, the second consisted of series of 9 visual fields from 150 eyes, and the third consisted of series of more than 9 visual fields (17.5 on average) from 139 eyes. Results: For a statistical significance of 0.05, the false-positive rates for ANSWERS were about 3 times greater than expected at 15%, 17%, and 16%, respectively, whereas for PoPLR they were 7%, 3%, and 6%. After equating the specificities at 0.05 for both models, positive rates for ANSWERS were 16%, 25%, and 38%, whereas for PoPLR they were 12%, 33%, and 49%, or about 5% greater on average (95% confidence interval = -1% to 11%). Conclusions: Despite being simpler and less computationally demanding, PoPLR was at least as sensitive to deterioration as ANSWERS once the specificities were equated. Translational Relevance: Close control of false-positive rates is key when visual fields of patients are analyzed for change in both clinical practice and clinical trials.

Indexed as

GlaucomaVisual FieldsDisease ProgressionHumansLinear ModelsVisual Field Tests

Identifiers

PMID34910103
PMCPMC8684309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.